Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lingze tablet plus tamsulosin vs tamsulosin alone for benign prostatic hyperplasia
ChiCTR2200062620Phase 4Not yet recruiting
- Sponsor
- Beijing University of Chinese Medicine
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tamsulosin and Lingze in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Beijing University of Chinese Medicine. Primary endpoint: International Prostate Symptom Score. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
tamsulosinLingze
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on ChiCTR2200062620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062620.